| Name | Tolimidone |
| Description | Tolimidone (NSC 314335) is a chemical compound which inhibits acid secretion in animal models and also acts as a bronchodilator in histamine-challenged animals. |
| Cell Research | Adipocyte differentiation is assessed in mouse 3T3-L1 cells after 8 days of incubation with MLR-1023 or rosiglitazone (10 μM).(Only for Reference) |
| In vitro | In an in vitro broad kinase screen MLR-1023 activated the nonreceptor-linked Src-related tyrosine kinase Lyn. MLR-1023 increased the Vmax of Lyn with an EC50 of 63 nM. This Lyn kinase activation was ATP binding site independent, indicating that MLR-1023 regulated the kinase through an allosteric mechanism[1]. |
| In vivo | MLR-1023-mediated blood glucose lowering depends on Lyn kinase activity[1]. MLR-1023 is an insulin receptor-potentiating agent that produces a rapid-onset and durable blood glucose-lowering activity in diabetic animals[2]. |
| Storage | 02 | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (9.89 mM), Sonication is recommended.
DMSO : 20.2 mg/mL (99.9 mM), Sonication is recommended.
Ethanol : 4 mg/mL (19.78 mM), Sonication is recommended.
|
| Keywords | Tolimidone | Src | NSC-314335 | NSC314335 | MLR1023 | MLR 1023 | Lyn kinase | Inhibitor | inhibit | CP26154 | CP 26154 |
| Inhibitors Related | Nintedanib | Vemurafenib | SI-2 hydrochloride | Staurosporine | Dasatinib | Ibrutinib | iHCK-37 | Pelitinib | Tofacitinib | Dasatinib monohydrate | TAK-901 | MCB-613 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | Anti-Metabolism Disease Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
